218 related articles for article (PubMed ID: 36647026)
21. Prevalence and Spectrum of
Foglietta J; Ludovini V; Bianconi F; Pistola L; Reda MS; Al-Refaie A; Tofanetti FR; Mosconi A; Minenza E; Anastasi P; Molica C; Stracci F; Roila F
Genes (Basel); 2020 Aug; 11(8):. PubMed ID: 32806537
[TBL] [Abstract][Full Text] [Related]
22. Racial and ethnic variation in multigene panel testing in a cohort of BRCA1/2-negative individuals who had genetic testing in a large urban comprehensive cancer center.
Tatineni S; Tarockoff M; Abdallah N; Purrington KS; Assad H; Reagle R; Petrucelli N; Simon MS
Cancer Med; 2022 Mar; 11(6):1465-1473. PubMed ID: 35040284
[TBL] [Abstract][Full Text] [Related]
23. Analysis of hereditary cancer syndromes by using a panel of genes: novel and multiple pathogenic mutations.
Tsaousis GN; Papadopoulou E; Apessos A; Agiannitopoulos K; Pepe G; Kampouri S; Diamantopoulos N; Floros T; Iosifidou R; Katopodi O; Koumarianou A; Markopoulos C; Papazisis K; Venizelos V; Xanthakis I; Xepapadakis G; Banu E; Eniu DT; Negru S; Stanculeanu DL; Ungureanu A; Ozmen V; Tansan S; Tekinel M; Yalcin S; Nasioulas G
BMC Cancer; 2019 Jun; 19(1):535. PubMed ID: 31159747
[TBL] [Abstract][Full Text] [Related]
24. Genetic counselors' perspectives on population-based screening for BRCA-related hereditary breast and ovarian cancer and Lynch syndrome.
De Simone LM; Arjunan A; Vogel Postula KJ; Maga T; Bucheit LA
J Genet Couns; 2021 Feb; 30(1):158-169. PubMed ID: 32562467
[TBL] [Abstract][Full Text] [Related]
25. Time to incorporate germline multigene panel testing into breast and ovarian cancer patient care.
Graffeo R; Livraghi L; Pagani O; Goldhirsch A; Partridge AH; Garber JE
Breast Cancer Res Treat; 2016 Dec; 160(3):393-410. PubMed ID: 27734215
[TBL] [Abstract][Full Text] [Related]
26. Inequities in multi-gene hereditary cancer testing: lower diagnostic yield and higher VUS rate in individuals who identify as Hispanic, African or Asian and Pacific Islander as compared to European.
Ndugga-Kabuye MK; Issaka RB
Fam Cancer; 2019 Oct; 18(4):465-469. PubMed ID: 31531760
[TBL] [Abstract][Full Text] [Related]
27. Prevalence of germline variants in consensus moderate-to-high-risk predisposition genes to hereditary breast and ovarian cancer in BRCA1/2-negative Brazilian patients.
Gomes R; Spinola PDS; Brant AC; Matta BP; Nascimento CM; de Aquino Paes SM; Bonvicino CR; Dos Santos ACE; Moreira MAM
Breast Cancer Res Treat; 2021 Feb; 185(3):851-861. PubMed ID: 33128190
[TBL] [Abstract][Full Text] [Related]
28. Association of Rare Pathogenic DNA Variants for Familial Hypercholesterolemia, Hereditary Breast and Ovarian Cancer Syndrome, and Lynch Syndrome With Disease Risk in Adults According to Family History.
Patel AP; Wang M; Fahed AC; Mason-Suares H; Brockman D; Pelletier R; Amr S; Machini K; Hawley M; Witkowski L; Koch C; Philippakis A; Cassa CA; Ellinor PT; Kathiresan S; Ng K; Lebo M; Khera AV
JAMA Netw Open; 2020 Apr; 3(4):e203959. PubMed ID: 32347951
[TBL] [Abstract][Full Text] [Related]
29. Penetrance estimates for
Evans DG; Woodward E; Harkness EF; Howell A; Plaskocinska I; Maher ER; Tischkowitz MD; Lalloo F
J Med Genet; 2018 Jul; 55(7):442-448. PubMed ID: 29483236
[TBL] [Abstract][Full Text] [Related]
30. "Decoding hereditary breast cancer" benefits and questions from multigene panel testing.
Colas C; Golmard L; de Pauw A; Caputo SM; Stoppa-Lyonnet D
Breast; 2019 Jun; 45():29-35. PubMed ID: 30822622
[TBL] [Abstract][Full Text] [Related]
31. The implications of BRCA loss of heterozygosity (LOH) and deficient mismatch repair gene (dMMR) expression in the breast cancer of a patient with both inherited breast and ovarian cancer syndrome (BRCA2) and Lynch syndrome (MLH1).
Sorscher S; Ansley K; Delaney SD; Ramkissoon S
Breast Cancer Res Treat; 2020 Apr; 180(2):511-514. PubMed ID: 32040686
[TBL] [Abstract][Full Text] [Related]
32. Phenotypic heterogeneity of hereditary gynecologic cancers: a report from the Creighton hereditary cancer registry.
Casey MJ; Bewtra C; Lynch HT; Snyder C; Stacy M; Watson P
Fam Cancer; 2013 Dec; 12(4):719-40. PubMed ID: 23666231
[TBL] [Abstract][Full Text] [Related]
33. Next Generation Sequencing-Based Germline Panel Testing for Breast and Ovarian Cancers in Pakistan.
Tariq H; Gul A; Khadim T; Ud-Din H; Tipu HN; Asif M; Ahmed R
Asian Pac J Cancer Prev; 2021 Mar; 22(3):719-724. PubMed ID: 33773534
[TBL] [Abstract][Full Text] [Related]
34. Power of pedigree likelihood analysis in extended pedigrees to classify rare variants of uncertain significance in cancer risk genes.
Rosenthal EA; Ranola JMO; Shirts BH
Fam Cancer; 2017 Oct; 16(4):611-620. PubMed ID: 28534081
[TBL] [Abstract][Full Text] [Related]
35. The uptake of presymptomatic genetic testing in hereditary breast-ovarian cancer and Lynch syndrome: a systematic review of the literature and implications for clinical practice.
Menko FH; Ter Stege JA; van der Kolk LE; Jeanson KN; Schats W; Moha DA; Bleiker EMA
Fam Cancer; 2019 Jan; 18(1):127-135. PubMed ID: 29846880
[TBL] [Abstract][Full Text] [Related]
36. Pathogenicity evaluation of BRCA1 and BRCA2 unclassified variants identified in Portuguese breast/ovarian cancer families.
Santos C; Peixoto A; Rocha P; Pinto P; Bizarro S; Pinheiro M; Pinto C; Henrique R; Teixeira MR
J Mol Diagn; 2014 May; 16(3):324-34. PubMed ID: 24607278
[TBL] [Abstract][Full Text] [Related]
37. Impact of Panel Gene Testing for Hereditary Breast and Ovarian Cancer on Patients.
Lumish HS; Steinfeld H; Koval C; Russo D; Levinson E; Wynn J; Duong J; Chung WK
J Genet Couns; 2017 Oct; 26(5):1116-1129. PubMed ID: 28357778
[TBL] [Abstract][Full Text] [Related]
38. Opportunistic testing of BRCA1, BRCA2 and mismatch repair genes improves the yield of phenotype driven hereditary cancer gene panels.
Feliubadaló L; López-Fernández A; Pineda M; Díez O; Del Valle J; Gutiérrez-Enríquez S; Teulé A; González S; Stjepanovic N; Salinas M; Capellá G; Brunet J; Lázaro C; Balmaña J;
Int J Cancer; 2019 Nov; 145(10):2682-2691. PubMed ID: 30927264
[TBL] [Abstract][Full Text] [Related]
39. BRCA1/2 variants of unknown significance in hereditary breast and ovarian cancer (HBOC) syndrome: Looking for the hidden meaning.
Fanale D; Pivetti A; Cancelliere D; Spera A; Bono M; Fiorino A; Pedone E; Barraco N; Brando C; Perez A; Guarneri MF; Russo TDB; Vieni S; Guarneri G; Russo A; Bazan V
Crit Rev Oncol Hematol; 2022 Apr; 172():103626. PubMed ID: 35150867
[TBL] [Abstract][Full Text] [Related]
40. Identification of hereditary breast and ovarian cancer germline variants in Granada (Spain): NGS perspective.
Molina-Zayas M; Garrido-Navas C; García-Puche JL; Barwell J; Pedrinaci S; Atienza MM; García-Linares S; de Haro-Muñoz T; Lorente JA; Serrano MJ; Poyatos-Andújar A
Mol Genet Genomics; 2022 May; 297(3):859-871. PubMed ID: 35451682
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]